Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 2,560 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 2,560 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Disc Medicine Stock Performance

Shares of Disc Medicine stock opened at $30.28 on Thursday. Disc Medicine, Inc. has a 52 week low of $23.30 and a 52 week high of $77.60. The stock has a 50 day moving average price of $56.51 and a two-hundred day moving average price of $55.57. The stock has a market capitalization of $730.96 million, a PE ratio of -8.68 and a beta of 0.18.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). Research analysts forecast that Disc Medicine, Inc. will post -4.44 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. BMO Capital Markets decreased their target price on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a research note on Tuesday, April 2nd. Stifel Nicolaus raised their target price on Disc Medicine from $71.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Morgan Stanley decreased their target price on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Wednesday, December 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research note on Monday, April 1st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.29.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC boosted its position in shares of Disc Medicine by 50.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 600 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the last quarter. Strs Ohio boosted its position in shares of Disc Medicine by 66.7% during the fourth quarter. Strs Ohio now owns 1,000 shares of the company’s stock valued at $57,000 after buying an additional 400 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Disc Medicine during the second quarter valued at approximately $28,000. Deutsche Bank AG boosted its position in shares of Disc Medicine by 27.3% during the third quarter. Deutsche Bank AG now owns 4,609 shares of the company’s stock valued at $217,000 after buying an additional 987 shares during the last quarter. Finally, AJOVista LLC purchased a new position in shares of Disc Medicine during the fourth quarter valued at approximately $63,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.